Patents by Inventor Li Liao
Li Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190293652Abstract: Methods are provided for identifying whether a tumor will be responsive to treatment with an anti-EGFR agent. Specific protein fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with an anti-EGFR agent such as, for example, pamitumumab and/or erbitux.Type: ApplicationFiled: January 20, 2017Publication date: September 26, 2019Applicants: Expression Pathology, Inc., NantOmics, LLCInventors: Fabiola CECCHI, Adele BLACKLER, Wei-Li LIAO, Todd HEMBROUGH, Daniel CATENACCI
-
Publication number: 20190265252Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the tyrosine-protein kinase receptor UFO protein (AXL) that are particularly advantageous for quantifying the AXL protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: February 12, 2019Publication date: August 29, 2019Inventors: David B. Krizman, Todd Hembrough, Adele Blackler, Wei-Li Liao
-
Patent number: 10310566Abstract: The present disclosure provides a foldable mechanism of a mobile terminal and the mobile terminal. The foldable mechanism includes a soft support structure and a hard support structure embedded in the soft support structure. The foldable mechanism formed by the soft support structure and the hard support structure embedded in the soft support structure is used as a component for connecting a first housing and a second housing. When the mobile terminal is unfolded, the foldable mechanism formed by the soft support structure and the hard support structure is unfolded and turns into a flat structure connected to the first housing and the second housing. When the mobile terminal is folded, one side of the soft support structure away from the hard support structure shrinks inward. Therefore, the mobile terminal is prevented from having an abrupt exterior structure, and an exterior effect of the mobile terminal is improved.Type: GrantFiled: August 31, 2018Date of Patent: June 4, 2019Assignee: HUAWEI TECHNOLOGIES CO., LTD.Inventors: Li Liao, Chia Huan Chang, Xin Zhu
-
Patent number: 10288616Abstract: Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.Type: GrantFiled: September 26, 2016Date of Patent: May 14, 2019Assignees: Expression Pathology, Inc., The University Of ChicagoInventors: Daniel Catenacci, Todd Hembrough, Fabiola Cecchi, Wei-Li Liao
-
Patent number: 10215761Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: September 12, 2016Date of Patent: February 26, 2019Assignee: Expression Pathology, Inc.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Publication number: 20190056406Abstract: The current disclosure provides methods for detecting and quantitating the 6-O-methylguanine-DNA methyltransferase protein (MGMT) directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed with formaldehyde containing agents/fixatives and may include formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and/or paraffin embedded. A protein sample is prepared from the biological sample and the MGMT protein is quantitated in the sample using SRM/MRM mass spectrometry by quantitating one or more fragment peptides.Type: ApplicationFiled: August 27, 2018Publication date: February 21, 2019Inventors: David B. KRIZMAN, Todd HEMBROUGH, Eunkyung AN, Sheeno THYPARAMBIL, Wei-Li LIAO
-
Patent number: 10203336Abstract: Peptides from the tyrosine-protein kinase receptor UFO protein (AXL) are provided that are particularly advantageous for quantifying the AXL protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM)/Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and include formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from the biological sample and the AXL protein is quantitated in the Liquid Tissue sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described.Type: GrantFiled: April 30, 2015Date of Patent: February 12, 2019Assignee: Expression Pathology, Inc.Inventors: David B. Krizman, Todd Hembrough, Adele Blackler, Wei-Li Liao
-
Patent number: 10202635Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Ephrin Type-A Receptor 2 (EPHA2) protein are provided that are particularly advantageous for quantifying the EPHA2 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: April 4, 2014Date of Patent: February 12, 2019Assignee: Expression Pathology, Inc.Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
-
Publication number: 20190033320Abstract: The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67) proteins that are particularly advantageous for quantifying the ER, PR, and/or Ki67 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: October 15, 2018Publication date: January 31, 2019Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Publication number: 20180373297Abstract: The present disclosure provides a foldable mechanism of a mobile terminal and the mobile terminal. The foldable mechanism includes a soft support structure and a hard support structure embedded in the soft support structure. The foldable mechanism formed by the soft support structure and the hard support structure embedded in the soft support structure is used as a component for connecting a first housing and a second housing. When the mobile terminal is unfolded, the foldable mechanism formed by the soft support structure and the hard support structure is unfolded and turns into a flat structure connected to the first housing and the second housing. When the mobile terminal is folded, one side of the soft support structure away from the hard support structure shrinks inward. Therefore, the mobile terminal is prevented from having an abrupt exterior structure, and an exterior effect of the mobile terminal is improved.Type: ApplicationFiled: August 31, 2018Publication date: December 27, 2018Applicant: HUAWEI TECHNOLOGIES CO., LTD.Inventors: Li LIAO, Chia Huan CHANG, Xin ZHU
-
Patent number: 10112500Abstract: An automobile quick charge control device include: an electric vehicle body, having a power generator; a power storage module, installed at the electric vehicle body and electrically connected to the power generator, and having batteries connected parallel to each other and having battery units and node switches respectively; a battery management system, electrically connected to the power storage module and the power generator, and the battery management system being electrically connected to the batteries and each node switch of the battery; a vehicle controller, electrically connected to the power storage module, the power generator and the battery management system, for reading information of the battery management system and monitoring the power storage module, and controlling the charge/discharge between the batteries. With the design of batteries and the operation of related control systems, a quick external charge for electric cars is achieved.Type: GrantFiled: February 1, 2016Date of Patent: October 30, 2018Inventors: Jen Li Liao, Yu Seng Liao, Wen Hua Liao Hu, Hsuan Hsien Liao, Fang Ying Liao
-
Patent number: 10101334Abstract: The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67) proteins that are particularly advantageous for quantifying the ER, PR, and/or Ki67 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: June 6, 2016Date of Patent: October 16, 2018Assignee: Expression Pathology, Inc.Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Patent number: 10041961Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Insulin Receptor protein (IR), and its isoforms IR-A and IR-B, that are particularly advantageous for quantifying the IR protein, IR-A isoform and/or IR-B isoform, directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: January 15, 2016Date of Patent: August 7, 2018Assignee: Expression Pathology, Inc.Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
-
Publication number: 20180195107Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins that are particularly advantageous for quantifying the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins directly in biological samples that have been fixed in formalin by the methods of Selected Reaction Monitoring (SRM) mass spectrometry, or as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: ApplicationFiled: December 11, 2017Publication date: July 12, 2018Inventors: David B. KRIZMAN, Todd HEMBROUGH, Sheeno THYPARAMBIL, Wei-Li LIAO
-
Publication number: 20180172690Abstract: Methods are provided for determining the diagnosis of whether a liver mass is a benign hepatocellular adenoma or a pre-malignant hepatocellular dysplastic nodule and/or a malignant hepatocellular carcinoma. Specific protein fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in liver mass cells collected from liver mass tissue that was obtained from a patient suffering from the liver mass and compared to reference levels in order to determine if the liver mass is a benign growth or a pre-cancer and/or cancer.Type: ApplicationFiled: April 20, 2017Publication date: June 21, 2018Inventors: Shahrooz RABIZADEH, Todd HEMBROUGH, Fabiola CECCHI, Christina YAU, David KRIZMAN, Wei-Li Liao, Sheeno Thyparambil
-
Patent number: 9840728Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins that are particularly advantageous for quantifying the ALK, Ros, Ron, Ret, TS, and/or FGFR1 proteins directly in biological samples that have been fixed in formalin by the methods of Selected Reaction Monitoring (SRM) mass spectrometry, or as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: September 15, 2015Date of Patent: December 12, 2017Assignee: Expression Pathology, Inc.Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Publication number: 20170330072Abstract: A method includes training an artificial neural network with training data that comprises a sets of design parameter values for design parameters for circuit traces in a high speed communication link, determining an output formula that relates a sets of design parameters to a corresponding output parameter for the circuit traces in response to training the artificial neural network, running the output formula using a second set of design parameter values to obtain a corresponding set of output parameters for the circuit traces, determining that the corresponding set of output parameters differ from a set of modeled output parameters by less than a predefined percentage, and fabricating a circuit trace in a printed circuit board based upon the output formula in response to determining that the corresponding set of output parameters differ from the set of modeled output parameters by less than the predefined percentage.Type: ApplicationFiled: May 11, 2016Publication date: November 16, 2017Inventors: Chun-Li Liao, Bhyrav M. Mutnury, Ching Huei (Carol) Chen, Nick Lee
-
Patent number: 9804164Abstract: Specific peptides, and derived ionization characteristics of the peptides, from the Fatty acid synthase (FASN) protein are provided that are particularly advantageous for quantifying the FASN protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: April 11, 2016Date of Patent: October 31, 2017Assignee: Expression Pathology, Inc.Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Patent number: 9804169Abstract: Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DR5) protein are provided that are particularly advantageous for quantifying the DR5 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: July 15, 2016Date of Patent: October 31, 2017Assignee: Expression Pathology, Inc.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
-
Patent number: 9766246Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: July 22, 2016Date of Patent: September 19, 2017Assignee: Expression Pathology, Inc.Inventors: David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough